Baseline plasma p-tau217/Aβ42 as a sensitive marker for the severity of Alzheimer's disease continuum - PubMed
5 hours ago
- #Biomarker
- #Cognitive assessment
- #Alzheimer’s disease
- Baseline plasma p-tau217/Aβ42 is identified as a sensitive marker for assessing the severity of Alzheimer's disease continuum.
- The study was approved by institutional review boards, with informed consent obtained from participants or their guardians, adhering to the Declaration of Helsinki.
- The authors declare no conflict of interest, ensuring the integrity of the research findings.
- References include significant works on biomarkers for neurodegenerative diseases and recent advancements in Alzheimer's treatment, such as Aducanumab, Lecanemab, and Donanemab.
- The research highlights the importance of plasma p-tau217/Aβ42 in cognitive assessment and its predictive performance in Alzheimer's disease.